Short Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2%

InflaRx (NASDAQ:IFRX) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 564,700 shares, an increase of 46.2% from the February 13th total of 386,300 shares. Based on an average trading volume of 382,600 shares, the short-interest ratio is presently 1.5 days. Approximately 1.0% of the company’s shares are sold short.

Hedge Funds Weigh In On InflaRx

Institutional investors have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new stake in InflaRx in the fourth quarter worth about $28,000. Walleye Capital LLC purchased a new stake in InflaRx in the fourth quarter worth about $51,000. Cubist Systematic Strategies LLC purchased a new stake in InflaRx in the fourth quarter worth about $55,000. Geode Capital Management LLC grew its holdings in InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock worth $119,000 after purchasing an additional 11,900 shares during the period. Finally, Commonwealth Equity Services LLC grew its holdings in InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after purchasing an additional 19,000 shares during the period. 42.39% of the stock is owned by institutional investors.

InflaRx Price Performance

IFRX stock opened at $1.19 on Friday. InflaRx has a 1 year low of $1.13 and a 1 year high of $2.82. The company has a market cap of $79.89 million, a P/E ratio of -1.10 and a beta of 1.98. The firm has a 50-day moving average of $2.03 and a 200 day moving average of $1.91.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of InflaRx in a research note on Friday, March 7th.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.